

Docket: 7210.03

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:

James L. Madara

Application No.:

10/762,388

Filing Date:

January 22, 2004

No. 1-1-4' C. C. C. C.

to Columnar Epithelia

Examiner:

Unknown

Title:

Modulation of Inflammation Related

Group Art Unit:

Unknown

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 I hereby certify that this document is being sent via First Class U.S. mail addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 23 day of 4261, 2004

Barlax a avery (Signature)

Dear Sir:

Pursuant to 37 CFR § 1.97(b), the references listed on the attached Form PTO-1449 (4 sheets, submitted in duplicate) are brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. This IDS is being filed before the mailing of a first office action on the merits. In accordance with 37 CFR § 1.97(b), no statement or fee is required.

Copies of the references cited are not enclosed, as allowed under 37 CFR § 1.98(d). Each item on the enclosed Form PTO-1449 was cited to, or cited by, the Office in U.S. Patent No. 6,353,026, issued on March 5, 2002 to which priority is claimed under 35 U.S.C. § 120, in the present application.

Respectfully submitted,

DORSEY & WHITNEY LLP Customer Number 25763

Date: Bail 23

By:

Scott D. Rothenberger, (Reg. No. 41,277)

Intellectual Property Department Suite 1500, 50 South Sixth Street Minneapolis, MN 55402-1498

(612) 340-8819

PTO/SB/08A (10/01) (modified) ... U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for form 1449A/PTO **Application Number** 10/762.388 January 22, 2004 **Filing Date** INFORMATION DISC **First Named Inventor** James L. Madara STATEMENT BY APPLICANT Art Unit Unknown (use as many sheets as necessary) Unknown **Examiner Name Sheet** 1 of 4 **Attorney Docket Number** 7210.03 **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, Where DOCUMENT NUMBER Cite Publication Date Name of Patentee or Relevant Passages or Initials No. Number - Kind Code (if known) MM-DD-YYYY Applicant of Cited Document Relevant Figures Appear 5,441,951 8-1995 Serhan US-5,648,512 7-1997 Serhan US-6,353,026 3-2002 Serhan US-10-2002 6,458,839 Madara et al. US-6,699,905 3-2004 Madara et al. US-US-FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENT Number - Kind Code Pages, Columns, Lines, TRANSLATION Country **Publication Date** \*Examiner Cite Name of Patentee or Where Relevant Passages Code: (if known) Initiat MM-DD-YYYY Applicant of Cited Document or Relevant Figures Appear YES NO **PCT** WO 94/29262 12-1994 П PCT WO 95/01179 1-1995 PCT WO 00/54767 9-2000 П **OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS** Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the TRANSLATION Examine: Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials No. number(s), publisher, city and/or country where published NO Weissmann, G., Smolen, J. E., and Korchak, H. M. (1980) Release of inflammatory mediators from stimulated neutrophils. N. Engl. J. Med. 303, 27-34 П Serhan, C. N., Haeggstrom, J. Z., and Leslie, C. C. (1996) Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10, 1147-1158 Weiss, S. J. (1989) Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365-376 

Serhan, C. N. (1994) Lipoxin biosynthesis and its impact in inflammatory and vascular events.

Borgeat, P., and Naccache, P. H. (1990) Biosynthesis and biological activity of leukotriene B4.

Biochim. Biophys. Acta 1212, 1-25

Clin. Biochem. 23, 459-468

П

П

				_					
Substitute for form 1449A/PTO					Application Number	10/762,388			
INEO		) NI L	ISCLOSUF	) <b>=</b>	Filing Date	January 22, 2004			
			APPLICAN		First Named Inventor	James L. Madara			
	_		as necessary)	4 1	Art Unit	Unknown			
,,,	oo ao many		uo 1/00000u.y/		Examiner Name	Unknown			
Sheet	2	of	4		Attorney Docket Number	7210.03			
	ОТ	HER I	DOCUMENTS -	· NOI	N-PATENT LITERATUR	E DOCUMENTS			
	Yokomizo, T., Izumi, T., Chang, K., Takuwa, T., and Shimizu, T. (1997) A G-protein-coupled receptor for leukotriene B₄ that mediates chemotaxis. <i>Nature</i> 387, 620-624								
	Fiore, S., Romano, M., Reardon, E. M., and Serhan, C. N. (1993) Induction of functional lipoxin A <sub>4</sub> receptors in HL-60 cells. <i>Blood</i> 81, 3395-3403								
		Isakson, P., Seibert, K., Masferrer, J., Salvemini, D., Lee, L., and Needleman, P. (1995) Discovery of a better aspirin. <i>Advances in Prostaglandin, Thromboxane &amp; Leukotriene Research</i> 23, 49-54							
	Chiang, N., Takano, T., Clish, C. B., Petasis, N. A., Tai, HH., and Serhan, C. N. (1998) Aspirintriggered 15-epi-lipoxin A <sub>4</sub> (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA <sub>4</sub> ELISA. <i>J. Pharmacol Exper. Ther.</i> 287, 779-790								
	Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P., and Madara, J. L. (1995) Design of lipoxin A <sub>4</sub> stable analogs that block transmigration and adhesion of human neutrophils. <i>Biochemistry</i> 34, 14609-14615								
	Takano, T., Fiore, S., Maddox, J. F., Brady, H. R., Petasis, N. A., and Serhan, C. N. (1997) Aspirin-triggered 15-epi-lipoxin A <sub>4</sub> (LXA <sub>4</sub> ) and LXA <sub>4</sub> Stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. <i>J. Exp. Med.</i> 185, 1693-1704								
	Owman, C., Garzino-Demo, A., Cocchi, F., Popovic, M., Sabirsh, A., and Gallo, R. (1998) The leukotriene B <sub>4</sub> receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. <i>Proc. Natl. Acad. Sci.</i> 95, 9530-9534								
	Marcus, A. J. (1995) Aspirin as prophylaxis against colorectal cancer. N. Engl. J. Med. 333, 656-658								
	Vainio, H., and Morgan, G. (1997) Aspirin for the second hundred years: new uses for an old drug. <i>Pharmacol Toxicol</i> 81, 151-152								
	Herschman, H. R. (1998) Recent progress in the cellular and molecular biology of prostaglandin synthesis. <i>Trends in Cardiovasc. Med.</i> 8, 145-150								
·	Takano, T., Clish, C. B., Gronert, K., Petasis, N., and Serhan, C. N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epilipoxin A <sub>4</sub> and novel lipoxin B <sub>4</sub> stable analogues. <i>J. Clin. Invest.</i> 101, 819-826								
	Billah, M. M., Eckel, S., Mullmann, T. J., Egan, R. W., and Siegel, M. I. (1989) Phosphatidylcholine hydrolysis by phospholipase D determines phosphatidate and diglyceride levels in chemotactic peptide-stimulated human neutrophils. Involvement of phosphatidate phosphohydrolase in signal transduction. <i>J. Biol. Chem.</i> 264, 17069-17077								
	P. G., and	d Reyn	O., Martin, A., Hoo olds, J. L. (1997) F vances in Enzyme	Role a	M. N., Brown, F., Pettit, T. R. nd regulation of phospholipas lation 37, 29-34	., Cross, M. J., De Takats, se D activity in normal and			

-- 1 + 5 + 10 +

to see

Substitute for form 1449A/PTO			1	Application Number	10/762,388					
INF	<b>O</b> F	2ΝΛΔΤΙζ	<b>ЭИ Г</b>	DISCLOSURE	Filing Date	January 22, 2004				
				APPLICANT	First Named Inventor	James L. Madara	James L. Madara			
317				as necessary)	Art Unit	Unknown				
	(60		31100.0	as necessary,	Examiner Name	Unknown				
Sheet	$\Box$	3	of	4	Attorney Docket Number	7210.03				
		ОТ	HER	DOCUMENTS - NOI	N-PATENT LITERATUR	E DOCUMENTS				
		Olson, S.	C., and	<del></del>	Biochemistry and cell biology					
	<u>-</u>		Steed, P. M., Clark, K. L., Boyar, W. C., and Lasala, D. J. (1998) Characterization of human PLD2 and the analysis of PLD isoform splice variants. <i>FASEB J.</i> 12, 1309-1317							
		Wakelam	Martin, A., Saqib, K. M., Hodgkin, M. N., Brown, F. D., Pettit, T. R., Armstrong, S., and Wakelam, M. J. O. (1997) Role and regulation of phospholipase D signalling. <i>Biochem. Soc. Trans.</i> 25, 1157-1160							
		Levy, B. [ signalling	Levy, B. D., Petasis, N. A., and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. <i>Nature</i> 389, 985-989							
		Agwu, D. E., McPhail, L. C., Sozzani, S., Bass, D. A., and McCall, C. E. (1991) Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on activation of NADPH oxidase. <i>J. Clin. Invest.</i> 88, 531-539								
		Pettit, T. R., Martin, A., Horton, T., Liossis, C., Lord, J. M., and Wakelam, M. J. O. (1997) Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. <i>J. Biol. Chem.</i> 272, 17354-17359								
		Gomez-C	Cambror	nero, J. (1995) Immunop	precipitation of a phospholipas eron Cytokine Res. 15, 877-88	se D activity with				
		Abousalham, A., Riviere, M., Teissere, M., and Verger, R. (1993) Improved purification and biochemical characterization of phospholipase D from cabbage. <i>Biochim. Biophys. Acta</i> 1158, 1-7								
,		Zhou, HL., Chabot-Fletcher, M., Foley, J. J., Sarau, H. M., Tzimas, M. N., Winkler, J. D., and Torphy, T. J. (1993) Association between leukotriene B <sub>4</sub> -induced phospholipase D activation and degranulation of human neutrophils. <i>Biochem. Pharmacol.</i> 46, 139-148								
`			Shechter, I., Fogelman, A. M., and Popjak, G. (1980) A deficiency of mixed function oxidase activities in the cholesterol biosynthetic pathway of human granulocytes. <i>J. Lipid Res.</i> 21, 277-							
•		Rabinowit	tz, J. L. les of a	, Baker, D. G., Villanuev dults taking therapeutic	va, T. G., Asanza, A. P., and C doses of aspirin. <i>Lipids</i> 27, 31	Capuzzi, D. M. (1992) Liver 1-314				
			Claria, J., and Serhan, C. N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. <i>Proc. Natl. Acad. Sci.</i> 92, 9475-9479							
					l Aspirin-Triggered 15-epi-Lipo y? <i>Prostaglandins</i> 53, 107-137					
		Exton, J.	H. (199	7) New developments in	n phospholipase D. <i>J. Biol. Ch</i>	nem. 272, 15579-15582				
		factor and	d Rho p	hatmore, J., Morgan, C., proteins mediate fMLP-de	Jones, D., and Cockcroft, S. ependent activation of phosph	(1998) ADP-ribosylation nolipase D in human				

Substitute for form 1449A/PTO					Application Number	10/762,388	10/762,388			
INIFC	JΩ	MATIO	N DI	SCLOSURE	Filing Date	January 22, 2004				
					First Named Inventor	James L. Madara				
	STATEMENT BY APPLICANT (use as many sheets as necessary)				Art Unit	Unknown				
(436 43	(use as many sneets as necessary)				Examiner Name	Unknown				
Sheet 4 of 4					Attorney Docket Number	7210.03				
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
		squalene.	Jarstfer, M. B., Blagg, B. S. J., Rogers, D. H., and Poulter, C. D. (1996) Biosynthesis of squalene. Evidence for a tertiary cyclopropylcarbinyl cationic intermediate in the rearrangement of presqualene diphosphate to squalene. <i>J. Amer. Chem. Soc.</i> 118, 13089-13090							
		Bach, T. 3 191-202	Bach, T. J. (1995) Some new aspects of isoprenoid biosynthesis in plantsa review. <i>Lipids</i> 30, 191-202							
		Serhan et al., "Aspirin-Triggered 15-EPI-Lipoxin A <sub>4</sub> and Novel Lipoxin B <sub>4</sub> Stable Analogs Inhibit Neutrophil-Mediated Changes in Vascular Permeability," <i>Advances in Experimental Medicine and Biology</i> , Vol. 469, 1999, pgs. 287-293								
		Inhibited b	Gewirzt et al., "Pathogen-Induced Chemokine Secretion from Model Intestinal Epithelium is Inhibited by Lipoxin A <sub>4</sub> Analogs", <i>Journal of Clinical Investigation</i> , Vol. 101, No. 9, May 1998, pgs. 1860-1869							
		Intracellul	ar Actic	on of Oxygenation Produ	ase C By Lipoxin A and Other ucts of Arachidonic Acid", <i>Biod</i> b. 3, 1986, pgs. 1215-1222					
			Olson et al., "Biochemistry and cell biology of phospholipase D in human neutrophils", Chemistry and Physics of Lipids, 80, pp. 3-19, 1996							
		Applicatio	Takano et al., "Neutrophil-mediated Changes in Vascular Permeability Are Inhibited by Topical Application of Aspirin-triggered 15-epi-lipoxin A4 and Novel Lipoxin B4 Stable Analogues", J. Clin. Invest. Volume 101, Number 4, February 1998, pp. 819-826							
			,							
EXAMIN	NER	SIGNATUR	E		DATE CONSIDERED			•		
*EXAMI	NEF	R: Initial if re	ference	considered, whether or r	not citation is in conformance w	ith MPEP 609. Draw line thro	ough			

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

in the same of the same

 $\frac{1}{2} \left( -\frac{t^2 r^{-1} d^4}{r^2} \right)$ 

al mark at a see .

5.5.1 along and mademank office, 5.5. DEFAITMENT OF COMM										LITOL			
Substitu	Substitute for form 1449A/PTO						ica	ation Number	10/762,388				
INIE	ΛE	RAATIA		ISCLO:	SHIDE	Filing Date		Date	January 22, 2004				
				APPLIC		First	First Named Inventor		James L. Madara				
317				as necessar		Art Ü	lni	it We work	Unknown				
	(us	e as many	SHEELS	as riecessar	<i>y)</i>	Examiner Name Unknown							
Sheet		1	of	4		Attori	Attorney Docket Number 7210.03						
			-t		U.S. PAT	TENT.	D	OCUMENTS		·			
*Examiner	Cite No.	DOCUMENT NUMBER  Number - Kind Code (if known)			Publication MM-DD-Y	n Date	Date Name of Patente						
			,441,951		8-1995		+	Serhan		7101074111119			
		US- 5,	,648,512	2	7-1997	1.	†	Serhan					
		US- 6,353,026		3-2002		†	Serhan						
		US- 6,458,839			10-2002		1	Madara et al.					
		US- 6,699,905			3-2004	į	1	Madara et al.					
		US-					T		N				
				F	OREIGN F	PATEN	N٦	T DOCUMENTS					
		FOREIGN	PATENT	DOCUMENT		Name of Patentee or Where Re							
*Examiner Initial	Cite No.	Country Code:		er - Kind Code i known)					Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		TRANSLA YES	NO NO	
		PCT	WO 94	1/29262	12-1994								
		PCT		5/01179	1-1995								
		PCT	WO 00	0/54767	9-2000	9-2000							
	*							Arguma Transferance					
_		ОТ	HER I	DOCUMEN	NTS - NOI	N-PAT	ГΕ	NT LITERATURE	E DOCUM	ENTS			
*Examiner	Cite No.	n	nclude nan	me of the author	(in CAPITAL l journal, serial,	ETTERS	S), ium	, title of the article (when ap n, catalog, etc.), date, page or country where published	opropriate), title	of the	TRANSLA		
		10/2:2									YES	NO	
-		from stim	nulated r	neutrophils.	N. Engl. J. N	/led. 30	3,	Marie Land					
•		Serhan, C. N., Haeggstrom, J. Z., and Leslie, C. C. (1996) Lipid mediator networks in cell signaling: update and impact of cytokines. <i>FASEB J.</i> 10, 1147-1158											
		Weiss, S	Weiss, S. J. (1989) Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365-376										
				994) Lipoxin s. Acta 1212		is and	its	s impact in inflammat	ory and vas	cular events.			
				Naccache,	P. H. (1990	) Biosyı	/nt	thesis and biological	activity of le	ukotriene B₄.	П	П	

Substitute	for form 1449A	√PTO		Application Number	10/762,388					
INIEC		<b>ЭМ Г</b>	NECI OCUDE	Filing Date	January 22, 2004					
_		_	DISCLOSURE APPLICANT	First Named Inventor	James L. Madara					
			as necessary)	Art Unit	Unknown	Unknown				
I	(use as many	3110013	as liecessary)	Examiner Name	Unknown	Unknown				
Sheet	2	of	4	Attorney Docket Number	7210.03					
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
				kuwa, T., and Shimizu, T. (1 chemotaxis. <i>Nature</i> 387, 620						
		Fiore, S., Romano, M., Reardon, E. M., and Serhan, C. N. (1993) Induction of functional lipoxin A <sub>4</sub> receptors in HL-60 cells. <i>Blood</i> 81, 3395-3403								
		y of a be		, Salvemini, D., Lee, L., an Prostaglandin, Thromboxan						
	triggered	Chiang, N., Takano, T., Clish, C. B., Petasis, N. A., Tai, HH., and Serhan, C. N. (1998) Aspirintriggered 15-epi-lipoxin A <sub>4</sub> (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA <sub>4</sub> ELISA. <i>J. Pharmacol Exper. Ther.</i> 287, 779-								
	Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P., and Madara, J. L. (1995) Design of lipoxin A₄ stable analogs that block transmigration and adhesion of human neutrophils. <i>Biochemistry</i> 34, 14609-14615									
	Aspirin-tri	Takano, T., Fiore, S., Maddox, J. F., Brady, H. R., Petasis, N. A., and Serhan, C. N. (1997) Aspirin-triggered 15-epi-lipoxin A <sub>4</sub> (LXA <sub>4</sub> ) and LXA <sub>4</sub> Stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. <i>J. Exp. Med.</i> 185, 1693-1704								
	leukotrien	Owman, C., Garzino-Demo, A., Cocchi, F., Popovic, M., Sabirsh, A., and Gallo, R. (1998) The leukotriene B <sub>4</sub> receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. <i>Proc. Natl. Acad. Sci.</i> 95, 9530-9534								
	Marcus, A 658	Marcus, A. J. (1995) Aspirin as prophylaxis against colorectal cancer. N. Engl. J. Med. 333, 656-								
		Vainio, H., and Morgan, G. (1997) Aspirin for the second hundred years: new uses for an old drug. <i>Pharmacol Toxicol</i> 81, 151-152								
	Herschma synthesis	Herschman, H. R. (1998) Recent progress in the cellular and molecular biology of prostaglandin synthesis. <i>Trends in Cardiovasc. Med.</i> 8, 145-150								
	changes	Takano, T., Clish, C. B., Gronert, K., Petasis, N., and Serhan, C. N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epilipoxin A <sub>4</sub> and novel lipoxin B <sub>4</sub> stable analogues. <i>J. Clin. Invest.</i> 101, 819-826								
	Phosphat levels in	tidylcho chemo	oline hydrolysis by phosp otactic peptide-stimulated	T. J., Egan, R. W., an pholipase D determines phos d human neutrophils. Invol . <i>J. Biol. Chem.</i> 264, 17069-1	sphatidate and diglyceride livement of phsophatidate					
	P. G., and	d Reyn		M. N., Brown, F., Pettit, T. R. and regulation of phospholipas						

and a second

...

				e e e e e e e e e e e e e e e e e e e			•			
Substitute	for form 1449/	<b>VPTO</b>		Application Number	10/762,388					
MEC		~NI	NOO! OCUDE	Filing Date	January 22, 2004					
_			DISCLOSURE	First Named Inventor	James L. Madara					
	(use as many sheets as necessary)			Art Unit	Unknown	Unknown				
(	use as many	' 511CC (3	as necessary)	Examiner Name	Unknown					
Sheet	3	of	4	Attorney Docket Number	7210.03					
	<b>O</b> 7	THER	DOCUMENTS - NOI	N-PATENT LITERATUR	E DOCUMENTS					
	Olson, S	6. C., and	· · · · · · · · · · · · · · · · · · ·	Biochemistry and cell biology						
				and Lasala, D. J. (1998) Char olice variants. <i>FASEB J</i> . 12, 1						
	Wakelan	Martin, A., Saqib, K. M., Hodgkin, M. N., Brown, F. D., Pettit, T. R., Armstrong, S., and Wakelam, M. J. O. (1997) Role and regulation of phospholipase D signalling. <i>Biochem. Soc. Trans.</i> 25, 1157-1160								
		Levy, B. D., Petasis, N. A., and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. <i>Nature</i> 389, 985-989								
	Agwu, D. E., McPhail, L. C., Sozzani, S., Bass, D. A., and McCall, C. E. (1991) Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on activation of NADPH oxidase. <i>J. Clin. Invest.</i> 88, 531-539									
	Pettit, T. R., Martin, A., Horton, T., Liossis, C., Lord, J. M., and Wakelam, M. J. O. (1997) Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. <i>J. Biol. Chem.</i> 272, 17354-17359									
	Gomez-Cambronero, J. (1995) Immunoprecipitation of a phospholipase D activity with antiphosphotyrosine antibodies. <i>J. Interferon Cytokine Res.</i> 15, 877-885									
	Abousalham, A., Riviere, M., Teissere, M., and Verger, R. (1993) Improved purification and biochemical characterization of phospholipase D from cabbage. <i>Biochim. Biophys. Acta</i> 1158, 1-7									
	Torphy,	Zhou, HL., Chabot-Fletcher, M., Foley, J. J., Sarau, H. M., Tzimas, M. N., Winkler, J. D., and Torphy, T. J. (1993) Association between leukotriene B <sub>4</sub> -induced phospholipase D activation and degranulation of human neutrophils. <i>Biochem. Pharmacol.</i> 46, 139-148								
;		Shechter, I., Fogelman, A. M., and Popjak, G. (1980) A deficiency of mixed function oxidase activities in the cholesterol biosynthetic pathway of human granulocytes. <i>J. Lipid Res.</i> 21, 277-								
•		Rabinowitz, J. L., Baker, D. G., Villanueva, T. G., Asanza, A. P., and Capuzzi, D. M. (1992) Liver lipid profiles of adults taking therapeutic doses of aspirin. <i>Lipids</i> 27, 311-314								
•		Claria, J., and Serhan, C. N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. <i>Proc. Natl. Acad. Sci.</i> 92, 9475-9479								
				Aspirin-Triggered 15-epi-Lipo						
	_			n phośpholipase D. <i>J. Biol. Ch</i>						
	factor an	nd Rho p		Jones, D., and Cockcroft, S. ependent activation of phosph						

man a star dig.

Substitute for form 1449A/PTO				Application Number	10/762,388						
INEC		NI D	ISCLOSURE	Filing Date	January 22, 2004	January 22, 2004					
				First Named Inventor	James L. Madara						
STATEMENT BY APPLICANT (use as many sheets as necessary)				Art Unit	Unknown						
(030 23	many sneets	20 11000	<i>554, y)</i>	Examiner Name	Unknown						
Sheet	4	of	4	Attorney Docket Number	7210.03						
OTHE	OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
	squalen	Jarstfer, M. B., Blagg, B. S. J., Rogers, D. H., and Poulter, C. D. (1996) Biosynthesis of squalene. Evidence for a tertiary cyclopropylcarbinyl cationic intermediate in the rearrangement of presqualene diphosphate to squalene. <i>J. Amer. Chem. Soc.</i> 118, 13089-13090									
		Bach, T. J. (1995) Some new aspects of isoprenoid biosynthesis in plantsa review. <i>Lipids</i> 30, 191-202									
	Neutrop	Serhan et al., "Aspirin-Triggered 15-EPI-Lipoxin A <sub>4</sub> and Novel Lipoxin B <sub>4</sub> Stable Analogs Inhibit Neutrophil-Mediated Changes in Vascular Permeability," <i>Advances in Experimental Medicine and Biology</i> , Vol. 469, 1999, pgs. 287-293									
	Inhibited	Gewirzt et al., "Pathogen-Induced Chemokine Secretion from Model Intestinal Epithelium is Inhibited by Lipoxin A₄ Analogs", <i>Journal of Clinical Investigation</i> , Vol. 101, No. 9, May 1998, pgs. 1860-1869									
	Intracell	Hansson et al., "Activation of Protein Kinase C By Lipoxin A and Other Eicosandoids. Intracellular Action of Oxygenation Products of Arachidonic Acid", <i>Biochemical and Biophysical Research Communications</i> , Vol. 134, No. 3, 1986, pgs. 1215-1222									
		Olson et al., "Biochemistry and cell biology of phospholipase D in human neutrophils", Chemistry and Physics of Lipids, 80, pp. 3-19, 1996									
	Applicat	Takano et al., "Neutrophil-mediated Changes in Vascular Permeability Are Inhibited by Topical Application of Aspirin-triggered 15-epi-lipoxin A4 and Novel Lipoxin B4 Stable Analogues", J. Clin. Invest. Volume 101, Number 4, February 1998, pp. 819-826									
		28 July 5									
EXAMIN	ER SIGNATU	RE		DATE CONSIDERED							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											